GREY:ATBPF - Post by User
Comment by
Goaweighon Feb 19, 2021 1:47pm
110 Views
Post# 32611311
RE:RE:RE:RE:RE:Why i am not accumulating
RE:RE:RE:RE:RE:Why i am not accumulatingI've been thinking about Off label applications, of course we need to get 346 approved first but if it completely buffers any negative effects of the nsaids part of the drug then it becomes an H2S delivery system and not an nsaids delivery system although the nsaids part may have benefits too, depending on the use. For IBD for instance the nsaids, even if effectively buffered may still have a negative effect on the gut, but maybe not, while the H2S may have a profoud positive effect. Same with Covid, and maybe the nsaids portion may be effective against brain swelling in the case of Alzhiemers, if indeed that is one of the problems, getting through the blood/brain barrier may be the problem.
Of course a Co. can't promote on the basis of it's drug having Off label potential but it would be fascinating if we knew what the possibilities were.
MrMugsy wrote: Goaweigh ... you also asked about COVID. I didn't responded to that one.
For COVID, you need to refer to the BioPUB conference call when Dan was specificially asked about a COVID trial. Dan said he wan't able to discuss at this time.
Cheers !